# Pyxis Oncology, Inc. (PYXS) · Edgar & Edgarette company card

> Pyxis Oncology (PYXS) saw revenue fall 14.2% in FY2025 to $14 million, operating margin -609% against a -3.8% median for pharmaceutical preparations, equity 58.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1782223 · fiscal year ended 2025-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/PYXS) · [JSON](https://www.pops4.com/boards/company/PYXS.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $14M |
| Revenue growth, 1 year | -14.2% |
| Revenue growth per year | — |
| Operating margin | -609.2% (prior year -554.1%) |
| Net margin | -574.5% |
| Operating cash flow | −$64M |
| Capital spending | $9,000 |
| Free cash flow | −$64M |
| Cash | $15M |
| Long-term debt | — |
| Total assets | $92M |
| Total equity | $53M |
| Equity ÷ assets | 58.4% |
| Return on equity | -149.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -16.86 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -609.2% in FY2025; revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $13.9M (FY2025). Experience: revenue down 14.2% on the year; operating margin -609.2%, down from -554.1%. Soundness: equity 58.4% of assets, return on equity -149.1%. Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $8.7M and $15.7M next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -609.2% against a -3.8% median; growth -14.2% against 13.7%.

Range logged 2026-09-20, receipt 521349a707f025d4, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-09-08 ([filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/0001193125-26-384386-index.htm))

## Recent filings

- DEF 14A · filed 2026-10-21 · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526427882/0001193125-26-427882-index.htm)
- 8-K · filed 2026-10-01 · 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000143774926031767/0001437749-26-031767-index.htm)
- 8-K · filed 2026-09-09 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526385901/0001193125-26-385901-index.htm)
- 8-K · filed 2026-09-08 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526384386/0001193125-26-384386-index.htm)
- 10-Q · filed 2026-08-13 · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526347913/0001193125-26-347913-index.htm)
- 8-K · filed 2026-08-13 · 2.02 Results of Operations and Financial Condition · [filing](https://www.sec.gov/Archives/edgar/data/1782223/000119312526347911/0001193125-26-347911-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001782223.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1782223

## Cite

POPS4, Edgar & Edgarette: Pyxis Oncology, Inc. (PYXS) company card, from the company's own SEC filings, accessed 2026-11-05, https://www.pops4.com/boards/company/PYXS. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.